Gang Zheng, M.D., Ph.D., and Aaron Mansfield, M.D., describe Mayo Clinic Laboratories’ liquid biopsy, which analyzes blood samples for genetic information to guide cancer treatment. The circulating tumor DNA assay uses next generation sequencing and complements the laboratory's cell-based cancer testing.

By Barbara J. Toman • November 29, 2022

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new assay for gastrointestinal stromal tumors, or GIST. The panel covers multiple mutations, to better inform diagnosis and treatment options.

By Barbara J. Toman • November 8, 2022

In this month's "Hot Topic," Kevin Halling, M.D., Ph.D., discusses new next generation sequencing testing for various tumor types and the rationale for the enhancements that were made; reviews gene additions that are now available in each of the panels; and briefly speaks about the work that was done to validate cytology specimens for use in the subpanels.

By MCL Education • November 7, 2022

In this "Test in Focus" episode of the "Answers From the Lab" podcast, Ruifeng (Ray) Guo, M.D., Ph.D., explains how Mayo Clinic Laboratories' comprehensive melanoma panel better informs prognosis and treatment.

By Barbara J. Toman • November 1, 2022

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new colorectal cancer panel. The assay covers more genes to better inform decision-making about prognosis, targeted therapies and a hereditary cancer syndrome.

By Barbara J. Toman • October 27, 2022

Ying-Chun Lo, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated lung panel can better guide clinical decision-making, particularly about targeted lung cancer therapies.

By Barbara J. Toman • October 25, 2022

Over the course of two days, Mayo Clinic’s 2022 Breast Cancer Care: Innovation, Disruptive Technologies and Early Adopters educational conference will bring you up to speed on the new therapeutics, technologies and techniques that could change the way you provide breast cancer care.

By Cory Pedersen • August 8, 2022

As a two-time brain tumor survivor, Alex Kraatz has been through more harrowing medical experiences in his 34 years than most people face in a lifetime. But Alex’s fighting spirit, coupled with precision laboratory testing and cutting-edge treatments, have propelled him forward, keeping him hopeful despite the odds.

By Robin Huiras-Carlson • July 11, 2022

This unique Mayo Clinic resource offers a novel portal into the study of gene mutations before they cause breast cancer.

By Chris J. Bahnsen • June 8, 2022

Wei Shen, Ph.D., explains Mayo Clinic Laboratories' new expert-backed, hereditary oncology panels, which use next-generation sequencing to identify genetic mutations linked to increased cancer risk. By only including clinically significant genes, the panels provide clarity on diagnosis, prognosis, and treatment approaches.

By Samantha Rossi • November 16, 2021

In this month’s “Hot Topic,” Anja Roden, M.D., discusses new entities and changes of terminology in the 2021 World Health Organization (WHO) classification of lung tumors as well as the nomenclature in small biopsies.

By MCL Education • November 1, 2021

PACE/State of CA/State of FL - This “Specialty Testing” webinar will discuss the collaborative effort which led to the discovery of Kelch like protein 11 (KLHL11) IgG as a specific biomarker of neurological autoimmunity associated testicular germ cell tumor.

By MCL Education • July 22, 2021

The genetic variability of glioma, and its more advanced relative glioblastoma, has made genetic testing to identify biomarkers associated with prognosis and treatment effectivity an integral component of care plan development. However, the acceleration of brain tumor research and discovery translates into an ever-changing testing environment.

By Robin Huiras-Carlson • June 9, 2021